ESTRO 2024 - Abstract Book

S3876

Physics - Image acquisition and processing

ESTRO 2024

containing lesions. This technique shows promise as a quantitative imaging biomarker in the prostate, subject to further technical validation and biological validation to understand the link between R2* and hypoxia [5]. This work was supported by the Cancer Research UK Manchester Centre award [CTRQQR-2021\100010].

Keywords: imaging biomarkers, SWI, prostate radiotherapy

References:

1. Milosevic, M. et al . ‘Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer.' Clin Cancer Res . 18, 2108-2114 (2012).

2. Hoskin, P. J. et al . 'Hypoxia in Prostate Cancer: Correlation of BOLD-MRI With Pimonidazole Immunohistochemistry Initial Observations.' Int. J. Radiat. Oncol. Biol. Phys . 68, 1065–1071 (2007).

3. Bano, W., Sritharan, K., Oelfke, U., Tree, A. & Wetscherek, A. 'Integration of T2* mapping in daily prostate MR-Linac workflow for hypoxia characterisation.' Proc. Intl. Soc. Mag. Reson. Med. (2022).

4. Shukla-Dave, A. et al . 'Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials.' J. Magn. Reson. Imaging. 49, e101–e121 (2019).

5. O’Connor, J. P. B. et al . 'Imaging biomarker roadmap for cancer studies.' Nat. Rev. Clin. Oncol. 14, 169–186 (2017)